Evidence map›Paper›PMID 42496308›Full record

ArticleJournal of xenobiotics2026

Safranal Enhances the Efficacy of Praziquantel Against

Azza Fahmy, Amany Mohammed Mohmmed Hegab, Hanan S Mossalem, Samah Sulaiman Abuzahrah, Saud Omar Alafghani, Alaaeldin Ahmed Hamza, Nouf Juaid, Amr Amin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of xenobiotics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Azza FahmyDepartments of Parasitology, Immunology & Drug Evaluation, Theodor Bilharz Research Institute, Giza 12411, Egypt.ORCID 0000-0002-4891-3357
Amany Mohammed Mohmmed HegabDevelopmental Pharmacology and Acute Toxicity Department, Egyptian Drug Authority (EDA), Formerly National Organization of Drug Control and Research, Giza 12112, Egypt.
Hanan S MossalemMedical Malacology Department, Theodor Bilharz Research Institute, Giza 12411, Egypt.
Samah Sulaiman AbuzahrahDepartment of Biological Sciences, College of Science, University of Jeddah, Jeddah 21589, Saudi Arabia.ORCID 0000-0002-8189-5998
Saud Omar AlafghaniDepartment of Histopathology, Al Hada Military Hospital, Taif 26792, Saudi Arabia.
Alaaeldin Ahmed HamzaBiology Department, Egyptian Drug Authority (EDA), Formerly National Organization of Drug Control and Research (NODCAR), Giza 12611, Egypt.ORCID 0000-0001-5450-1116
Nouf JuaidDepartment of Clinical Laboratory Science, Inaya Medical College, Riyadh 12211, Saudi Arabia.ORCID 0009-0009-2862-4652
Amr AminDepartment of Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.ORCID 0000-0001-8888-1102

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although praziquantel (PZQ) is the main antischistosomal drug currently in use, concerns remain regarding incomplete reversal of schistosomiasis-induced pathology and the emergence of drug resistance. This study evaluates the combined effect of PZQ with safranal, a bioactive saffron constituent, on

Indexed as

antifibrotic therapyanti-inflammatory effectsantioxidantexperimental murine modelsafranalSchistosoma mansoni

Identifiers

PMID42496308
PMCPMC13397992

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.